Retirement Systems of Alabama Sells 1,853 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Retirement Systems of Alabama decreased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 286,593 shares of the medical equipment provider’s stock after selling 1,853 shares during the period. Retirement Systems of Alabama owned 0.08% of Intuitive Surgical worth $96,685,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ISRG. Baystate Wealth Management LLC raised its position in shares of Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares during the last quarter. MCF Advisors LLC grew its holdings in shares of Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 40 shares in the last quarter. Atticus Wealth Management LLC grew its holdings in shares of Intuitive Surgical by 85.4% in the fourth quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 41 shares in the last quarter. OFI Invest Asset Management purchased a new position in shares of Intuitive Surgical in the third quarter valued at $25,000. Finally, Headinvest LLC purchased a new position in shares of Intuitive Surgical in the third quarter valued at $28,000. Institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Piper Sandler raised their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday, April 19th. Truist Financial raised their target price on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. BTIG Research lifted their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. StockNews.com lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Finally, Citigroup lifted their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG traded up $2.21 on Friday, hitting $375.33. 927,845 shares of the company’s stock were exchanged, compared to its average volume of 1,564,565. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76. The stock has a market capitalization of $133.13 billion, a price-to-earnings ratio of 67.75, a price-to-earnings-growth ratio of 4.85 and a beta of 1.36. The business’s 50 day simple moving average is $386.19 and its two-hundred day simple moving average is $346.29.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the company earned $1.00 earnings per share. Equities analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insider Activity at Intuitive Surgical

In related news, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now directly owns 26,877 shares in the company, valued at $10,349,795.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares in the company, valued at $736,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the transaction, the vice president now owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The disclosure for this sale can be found here. Insiders sold 249,418 shares of company stock worth $96,300,959 over the last three months. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.